BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 11115086)

  • 1. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
    Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
    Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
    Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid.
    Ishikawa N; Miyata T; Ueda Y; Inagi R; Izuhara Y; Yuzawa H; Onogi H; Nishina M; Nangaku M; Van Ypersele De Strihou C; Kurokawa K
    Kidney Int; 2003 Jan; 63(1):331-9. PubMed ID: 12472800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids.
    Schalkwijk CG; Posthuma N; ten Brink HJ; ter Wee PM; Teerlink T
    Perit Dial Int; 1999; 19(4):325-33. PubMed ID: 10507813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid.
    Inagi R; Miyata T; Ueda Y; Yoshino A; Nangaku M; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 2002 Aug; 62(2):679-87. PubMed ID: 12110033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
    Zeier M; Schwenger V; Deppisch R; Haug U; Weigel K; Bahner U; Wanner C; Schneider H; Henle T; Ritz E
    Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.
    le Poole CY; van Ittersum FJ; Valentijn RM; Teerlink T; Lindholm B; Ter Wee PM; Schalkwijk CG
    Perit Dial Int; 2012; 32(1):45-54. PubMed ID: 21632443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis.
    Tauer A; Bender TO; Fleischmann EH; Niwa T; Jörres A; Pischetsrieder M
    Mol Nutr Food Res; 2005 Jul; 49(7):710-5. PubMed ID: 15915443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure- and concentration-specific assessment of the physiological reactivity of α-dicarbonyl glucose degradation products in peritoneal dialysis fluids.
    Distler L; Georgieva A; Kenkel I; Huppert J; Pischetsrieder M
    Chem Res Toxicol; 2014 Aug; 27(8):1421-30. PubMed ID: 25033248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the formation of glucose degradation products in peritoneal dialysis solutions by ultrahigh temperature ohmic heating.
    Shapira A; Shazman A; Ungar Y; Shimoni E
    Mol Nutr Food Res; 2007 Apr; 51(4):473-8. PubMed ID: 17390399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions.
    Ho-dac-Pannekeet MM; Weiss MF; de Waart DR; Erhard P; Hiralall JK; Krediet RT
    Perit Dial Int; 1999; 19 Suppl 2():S68-74. PubMed ID: 10406497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation.
    Miyata T; Ueda Y; Asahi K; Izuhara Y; Inagi R; Saito A; VAN Ypersele DE Strihou C; Kurokawa K
    J Am Soc Nephrol; 2000 Sep; 11(9):1719-1725. PubMed ID: 10966497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin.
    Posthuma N; ter Wee PM; Niessen H; Donker AJ; Verbrugh HA; Schalkwijk CG
    Perit Dial Int; 2001; 21(1):43-51. PubMed ID: 11280495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of peritoneal fluid and solute transport with combination of glucose and icodextrin as osmotic agents.
    Galach M; Werynski A; Waniewski J; Freida P; Lindholm B
    Perit Dial Int; 2009; 29(1):72-80. PubMed ID: 19164256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
    Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
    Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis.
    Linden T; Forsbäck G; Deppisch R; Henle T; Wieslander A
    Perit Dial Int; 1998; 18(3):290-3. PubMed ID: 9663893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.
    Schmitt CP; von Heyl D; Rieger S; Arbeiter K; Bonzel KE; Fischbach M; Misselwitz J; Pieper AK; Schaefer F;
    Nephrol Dial Transplant; 2007 Jul; 22(7):2038-44. PubMed ID: 17420168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo generation and kinetics of glycosylation products in peritoneal dialysis effluents.
    Yokota S; Kumano K; Hyodo T; Sakai T; Izumi G; Hashimoto A; Shibata K; Wang H
    Adv Perit Dial; 1998; 14():195-9. PubMed ID: 10649723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis.
    García-López E; Pawlaczyk K; Anderstam B; Qureshi AR; Kuzlan-Pawlaczyk M; Heimbürger O; Werynski A; Lindholm B
    Perit Dial Int; 2007; 27(4):415-23. PubMed ID: 17602150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.